Launched by AKF in November 2020, the UCKD Project works to expand access to genetic testing, reduce systemic inequities, engage providers and empower patients. Implementation groups have concentrated ...

LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VYGR), a biotechnology company dedicated to advancing ...

Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter. Click here to read more about its fund ...

Covid-19 underlined the critical importance of vaccines. The pandemic caused 16 million global deaths, and the current scare ...

When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

Gefurulimab is under clinical development by Alexion Pharmaceuticals and currently in Phase III for Myasthenia Gravis.

An AstraZeneca subsidiary owes $130 million to ... Morgan Zurn decided in an opinion that followed a seven-day trial. Alexion Pharmaceuticals Inc. could later be ordered to pay more in damages ...

Alexion Pharmaceuticals Inc. could later be ordered to pay more in damages for another claim in which Zurn ruled against it, ...

Alexion reached payment trigger, should have tried for more Judge ties breaches to $39 billion AstraZeneca acquisition An AstraZeneca Plc subsidiary is liable for more than $130 million in damages ...

NYSE:NVS) Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14 ...

Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics ...